WHAT IS KNOWN AND OBJECTIVE: For over 50 years, @entity1229 was the only oral anticoagulant approved in the United States. In 2011, the Food and Drug Administration (FDA) approved @entity3925 . Since its introduction, @entity3925 has served as an alternative to @entity1229 to minimize drug interactions and avoid drug monitoring. The objective of this study was to evaluate the appropriateness of @entity3925 dosing, indication and safety in a community hospital and to identify areas for improvement in its use. METHODS: This single-centre, retrospective review evaluated @entity1 who received at least one dose of @entity3925 between November 2011 and July 2013. The primary outcome included appropriateness of the first day of therapy based on indication and renal function per FDA-approved dosing recommendations for the prevention of @entity64 in non-valvular @entity955 (NVAF) and for the treatment or prevention of @entity1211 ( @entity1211 ). The secondary outcome included incidence of major @entity548 or non-major clinically relevant @entity548 . RESULTS AND DISCUSSION: Of the 445 @entity1 evaluated, 36  9% of @entity1 treated for NVAF and 12  4% treated for @entity1211 were on an inappropriate regimen. Major @entity548 within 12 months occurred in 3  5% of @entity1 treated for NVAF, 1  2% for @entity1211 and 0% for off-label indications with a similar trend for non-major clinically relevant @entity548 (3  8%, 1  8% and 0%, respectively). WHAT IS NEW AND CONCLUSION: Though offering potential advantages over @entity1229 , the use of @entity3925 should be monitored to increase appropriateness of therapy and improve @entity1 safety. Therapeutic interchanges, pharmacist-directed interventions and other initiatives can be implemented to ensure appropriate use.

Evaluation of the appropriateness of dosing, indication and safety of XXXX in a community hospital.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity64 :: ('MESH:D020521', 'Disease') :: ['stroke and systemic embolism'] @entity548 :: ('MESH:D006470', 'Disease') :: ['bleeding'] @entity3925 :: ('MESH:C503223', 'Chemical') :: ['rivaroxaban'] @entity955 :: ('MESH:D001281', 'Disease') :: ['atrial fibrillation'] @entity1211 :: ('MESH:D054556', 'Disease') :: ['VTE', 'venous thromboembolism'] @entity1229 :: ('MESH:D014859', 'Chemical') :: ['warfarin']
@entity3925 :: (MESH:C503223,Chemical) :: ['rivaroxaban']
